Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide

Abstract

Diabetic foot ulcers are clinical complications that affect to a 15-25% of patients of type-2 diabetes mellitus and are responsible for more hospitalizations than any other complication of diabetes. Authors of US2019070266 patent propose a method for treatment of diabetic foot ulcers. US2019070266 describes a method that consists of the administration of Liraglutide, at a dose of 1.2-1.8 mg, in patients with type 2 diabetes and with at least one risk factor for vascular disease, such as microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction and ankle/brachial index <0.9. The results of the clinical trials support the therapy’s efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration of Liraglutide.